Biologics Price Competition and Innovation Act of 2009

The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) amends the Public Health Service Act (PHS Act) to create an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. The BPCI Act is closely related to the Drug Price Competition and Patent Term Restoration Act of 1984 (or referred to as the "Hatch-Waxman Act"), which established abbreviated pathways for the approval of drug products under the Federal Food, Drug, and Cosmetic Act (FD&C Act).[1][2]

References

Research, Center for Drug Evaluation and. "Information on Biosimilars". www.fda.gov.
"Archived copy" (PDF). Archived from the original (PDF) on 2015-11-29. Retrieved 2016-05-13.CS1 maint: archived copy as title (link)

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Research, Center for Drug Evaluation and. "Information on Biosimilars". www.fda.gov.

[2] "Archived copy" (PDF). Archived from the original (PDF) on 2015-11-29. Retrieved 2016-05-13.CS1 maint: archived copy as title (link)